ResMed (NYSE: RMD) reported Q3 EPS of $2.86, $0.05 better than the analyst estimate of $2.81. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.42 billion.

For earnings history and earnings-related data on ResMed (RMD) click here.